LabGenius, a London-based drug discovery company, has raised £35M in a Series B funding round led by M Ventures. The company uses machine learning and a smart robotic platform to discover new therapeutic antibodies. LabGenius operates under a hybrid business model and is also developing its own therapeutic pipeline.
Previous ArticleCognitive Analytics Market To Expand At 37.3% Cagr, Hitting Usd 48 Billion By 2026 As Revealed In New Report
Next Article Edit Your Robots: Obvious Signs Copy Is Ai Generated